Introduction
Colorectal cancer (CRC), one of the most prevalent cancers in the world, consists of a group of histologically heterogeneous diseases involving distinct tumorigenic pathways.
It ranks as the second leading death from cancer in the United States (1) and the fourth in China (2) . Mortality from CRC is mainly due to metastatic disease detected in at least half of the cases (3) . Untreated patients with liver metastases have a 5-year survival rate of a mere 2% (4) . Even though numerous genes have been implicated in colon tumorigenesis, only a few of them have been validated as biomarkers for predicting metastasis and treatment response.
High mobility group A (HMGA) gene family includes four chromatin-binding proteins:
HMGA1a, HMGA1b, HMGA1c, and HMGA2. Each of them contains three "AT-hooks", the functional motif characteristic of the HMGA family (5) . HMGA2 encodes a small, non-histone chromatin-associated protein that has no intrinsic transcriptional activity but can modulate transcription by altering the chromatin architecture (6, 7) . In humans, the HMGA2 gene is located at chromosome 12q14 and encodes a 109 amino-acid protein.
HMGA2 is expressed during embryogenesis but is absent or present at low levels in terminally differentiated tissues. In embryonic tissues, HMGA2 reportedly plays a critical role in stimulating normal cardiogenesis (8) , and mouse central and peripheral neural stem cell self-renewal (9) , thereby regulating cell growth and differentiation. HMGA2 is overexpressed in many malignant neoplasms (5, 10, 11) , and overexpression of HMGA2 is a poor prognostic factor for lung cancer (12) , oral squamous cell carcinoma (13) , ovarian cancer (14) , and metastatic breast cancer (15) . Expression of HMGA2 has been found to be related to Dukes stages and metastasis of CRCs in a cross-section study (16) .
However, it is not known whether HMGA2 overexpression is associated with the survival of CRCs nor if HMGA2 is related to response of therapies for any cancer type. 
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In this study, we investigated whether the HMGA2 level is associated with the survival of CRC patients. We optimized the conditions of immunohistochemistry for HMGA2 and conducted an outcome study on a training set with 89 CRC cases collected from City of Hope National Medical Center. In addition, we validated our finding using 191 cases collected from the 2 nd affiliated hospital of Zhejiang University. Our findings suggest that HMGA2 associates with poor prognosis and may serve as a biomarker for advanced CRC. (Table 1 ). All TNM stage data was obtained from clinical and pathological diagnosis. Primary tumor samples were obtained from surgical operation.
Study design
To avoid biases, standards and conditions of Immunohistochemistry (IHC) for HMGA2 expression determination were optimized on the training set (multiple tissue board, MTB) and validated on the validation set (multiple tissue array, MTA The above information was coded and entered into a CRC database. Double data entry and logic checks were used for error reduction.
Sample size was calculated using parameter estimates obtained from a pilot study previously conducted at City of Hope. Using nQuery Advisor 6.01 software, it was determined that a sample size of 190 patients would be needed for about 80% power with a two-sided α of 0.05. All patients were periodically followed for survival; patients with curative operations were also followed for recurrence-free survival. The follow-up period was calculated from the date of surgery until the date of last contact. The time of disease-free survival was defined as at the time of initial surgical therapy to tumor recurrence. Metastasis or local relapse was considered evidence of tumor recurrence. Only deaths from CRC were considered as endpoint of disease specific survival.
Construction of multiple tissue array (MTA) and multiple tissue board (MTB)
In the training set, all tissue samples were reassembled as multiple tissue board (MTB).
Each MTB contained 8-12 pieces of sections, and each piece is approximately 1mm × 10mm. The tumor blocks also contained both tumor and normal colorectal tissue samples as positive and negative controls for each IHC staining.
To validate the IHC results yield from MTB, the multiple tissue array blocks were constructed using 2mm cores taken from archival, routinely processed, paraffin- 
Quantitative immunohistochemistry assays
Immunohistochemistry (IHC) was used to investigate the HMGA2 protein expression.
The accuracy of IHC was validated by qRT-PCR on two parallel samples. The details of deparaffinization and IHC were described previously (17) . Briefly, after deparaffinization, the endogenous peroxidase activity was blocked with 3% H 2 O 2 . The array slides were incubated with normal goat serum for 20 minutes, and then applied with primary antibody for 20 minutes at room temperature. After 7 minutes of hydrogen peroxide treatment, the array slides were incubated with horseradish peroxidase-labeled polymer conjugated with corresponding antibodies for 30 minutes. Then, 3, 3-diaminobenzidine (0.05 g of 3, 3-diaminobenzidine and 100 mL of 30% H 2 O 2 in 100 mL of PBS) was applied for 5 and 10 minutes, respectively. Each slide was counterstained with hematoxylin (DAKO, Carpinteria, CA). PBS was used as a negative control.
The rabbit antibody against HMGA2 was purchased from Alexis BioCheck Company (Foster City, CA) and applied for IHC staining (1:1000 dilution). Pre-selection of HMGA2 antibody was according to western blot ( Supplementary Fig. 1 ), the optimized IHC condition was based on a serial dilution. To reduce the image reader bias, an automated imaging system was employed to obtain digital images of the stained sections for subsequent quantitative analyses. In addition, each sample was evaluated by two independent investigators in a double-blind manner. Investigators reviewed and assessed the subcellular localization (e.g., cytoplasm vs. nucleus), staining intensity (e.g., In generally, HMGA2 was predominantly nuclear staining in IHC. However, the HMGA2 was heterogeneously expressed between and within tumors. Some perinuclear granulation in cytoplasm was also observed. HMGA2 expression was quantified using a visual grading system based on the extent of staining. Only immunoreactivity in the nucleus was evaluated. HMGA2 was: negative (-) : <5% positive nuclear staining from (Table 1) .
To validate this finding, non-conditional Logistic analysis was employed for uni-and multivariate analyses. The HMGA2 positive and negative were stratified as unfavorable and favorable subsets, respectively. Tumor invasion, lymph node involvement, and distant organ metastasis were considered as the endpoint in Logistic analysis. The expression of HMGA2 significantly impacted the risk of distant metastasis but not tumor invasion and lymph node involvement according to either uni-or multivariate analysis.
After adjusting for age and sex, the odds ratio (OR) of HMGA2-positive CRC for metastasis were 3.53 (95% CI 1.37-9.70) and 6.38 (95% CI 1.47-43.95) for the training set and validation set, respectively (Supplement Table 1 ). Therefore, our analyses revealed that HMGA2 significantly impacts distant metastasis of CRC, suggesting that HMGA2 may be used to prognosticate CRCs.
Positive HMGA2 correlates with poor prognosis in CRCs.
To examine the hypothesis that HMGA2 may impact the survival of CRC patients, the COX hazard proportional model and Kaplan-Meier analysis were employed to analyze survivability. In the training set, the longest follow-up time is 213 months; 60 out of 89 patients with CRC died from CRC-related disorders and 67 cases had recurrence during the observation period. In the validation set, the longest follow-up time is 99.3 months; a total of 52 cases died from CRC and 65 CRC cases relapsed.
The Kaplan-Meier analysis result for OS is displayed in Fig. 2A and 2B (upper panels).
The Log-rank test indicated that the positive HMGA2 is significantly related to OS in both the training and validation sets (p < 0.05). In addition, the HMGA2 expression in primary CRC inversely correlated with the median survival time in the training and validation sets. The "strong positive" HMGA2 (++) exhibited a significantly reduced survivability (p<0.05). The recurrence analysis (Fig 2C and 2D. ) confirmed that the strong positive HMGA2 status significantly increased the risk for recurrence in both training and validation sets.
To avoid confounder effects, the multivariate COX analysis was conducted on both training and validation sets (Fig 2E & 2F , and Supplement Table 2 ). In the training set, factors including TNM stage, tumor location, gender and age were applied to adjust the hazard ratio (HR). To reduce the variance yield from insufficient sample size of the analysis, HMGA2 (+) and HMGA2 (++) were merged together as HMGA2-positive in COX proportional analysis. As illustrated in Fig. 2E& 2F, HMGA2 and TNM stages were significantly associated with poor OS of CRC for both training and validation sets with HRs for HMGA2 of 2.38 (95% CI 1.30-4.34) and 2.14 (95% CI 1.21-3.79), respectively. The HR of TNM stage also exhibited a comparable value in both sets, supporting the accuracy of our study. The tumor location significantly affected the prognosis in the training set, but it was not a significant contributing factor for the validation set (Supplement Table 2 ). The unexpected variance may be caused by small sample size of rectal cancer (only 7 cases) in the training set ( Table 1 ). The gender and age did not correlate significantly with CRC survival in both sets. Overall, our analyses revealed that HMGA2 was significantly associated with the poor survival of CRC patients.
HMGA2 impacts the survival of CRC patients with Stage III-IV.
Research. To confirm our finding, we analyzed the OS and PFS in different stages. As shown in Table 2 (Table 2) . Moreover, the Kaplan-Meier analysis revealed that the expression level of HMGA2 negatively relates to the median of OS time in a dose-dependent manner for the training set (Fig. 3A) . Similar results also could be seen in the validation set (Fig. 3B) .
The pathoclinical features of cancer for rectum and colon are different, suggesting that HMGA2 may impact the survival of colon and rectal cancer patients differently. In order to address this possibility, all CRCs were stratified by tumor location for further analysis in the second panel of Table 2 . In the training set, the positive HMGA2 was associated with worse survival of colon cancer, the HRs of OS and PSF were 1.44 (95% CI 0.81-2.50) and 1.33 (95% CI 0.76-2.24), respectively. Nevertheless, the Kaplan-Meier analysis revealed that the expression level of HMGA2 was inversely correlated with median OS of colon cancer in training set (log-rank p = 0.026) (Fig. 3C) . However, it was not feasible to assess rectal cancer due to insufficient number of cases (only seven). In the validation set, positive HMGA2 was significantly associated with worse OS and PFS of rectal cancer patients (p < 0.05) than colon cancer. The HRs of HMGA2 for OS and PFS were 2.79 (95% CI 1.33-5.96) and 2.85 (95% CI 1.36-6.09), respectively. An additional Kaplan-Meier analysis revealed that the expression level of HMGA2 inversely correlated with the median OS of rectal cancer in the validation set (Fig. 3D) 
Discussion
In this report, we examined the expression level of HMGA2 in CRCs to assess its potential role as a prognostic or predictive marker. Our findings revealed that the positive expression of HMGA2 was significantly associated with the distant metastasis in both training and validation sets (p < 0.05). The adjusted odd ratios (ORs) of HMGA2 for the risk of distant metastasis were 3.53 (95% CI 1.37-9.70) and 6.38 (95% CI 1.47-43.95) on training and validation sets, respectively. Previous studies, which showed that the HMGA2 mRNA expression was significantly escalated in invasive breast cancer cell lines for HMGA2, translocations often affect the third intron leading to the expression of fusion transcripts containing three AT-hooks and ectopic sequences of different origin (24) . Also, a mutation in the breast cancer susceptibility gene BRCA1 has been shown to de-repress HMGA2 in breast cancer cells (25) . Transgenic mice expressing a truncated form of the HMGA2 protein comprising the first three binding domains exhibit a giant phenotype with high incidence of lipomas. These results indicate that primarily truncation and/or aberrant expression of HMGA2 rather than its fusion to other genes is responsible for neoplastic transformation (26, 27) . The overexpression of HMGA2 occurs in various benign and malignant tumors. Disruption of the HMGA2 gene by rearrangements affecting the chromosome region 12q13-15 and the attendant overexpression of the HMGA2 protein results in several benign mesenchymal tumors such as lipoma and uterine leiomyoma (28) (29) (30) . Several independent studies have identified the HMGA2 transcript as a target for the let-7 family of microRNAs (31, 32) . Notably, a study investigating breast cancer-initiating cells suggested that silencing of HMGA2 enhances differentiation but not self-renewal (33) . In addition, HMGA2 interacts with pRb and enhances the E2F1 activity by displacing histone deacetylase 1 (HDAC1) (34) . Based on the results obtained using uterine leiomyomas, a balance between HMGA2 and the p19 ARF -TP53-CDKN1A has been proposed to determine the tumor size (35) . All these data support our notion that the degree of HMGA2 overexpression is one of the key elements determining the aggressiveness of CRC, affecting the survival of CRC patients. (38) . The mutant KRAS/BRAF is implicated for resistance to EGFR inhibiting drugs for late stage CRC (36) . Our study demonstrates that HMGA2 is relevant to metastasis and impacts the survival in advanced stage CRC.
Moreover, all these findings had been validated with participants from different racial background. There are many outcome-related factors for CRCs with different racial background, such as risk factors, genomic variations, medical care and social economic classes (39) . Therefore, the fact that identical results were yielded from two sets with different racial backgrounds further validates that HMGA2 is potentially an independent useful prognostic factor for predicting metastasis and survival for CRC patients.
The expression of HMGA2 was shown to increase the cytotoxic effect of DNA double strand breaks (DSB) induced by certain topoisomerase type II inhibitors, irradiation and the chemotherapeutic agent cisplatin but not the genotoxic agent hydroxyurea, MMS and low pH (19, 20, 40) . Our data demonstrated that overexpression of HMGA2 delayed the clearance of γ-H2AX after 3Gy γ-ray irradiation on HCT-116 and SW480 cells (Fig. 4B) .
HMGA2 disrupts the DSBs repair by altering the binding affinity between Ku and DNA ends, and delaying the release of DNA-PKcs from DSBs (20) . Therefore, the inhibition of NHEJ by HMGA2 facilitated the accumulation of chromosomal aberrations, which suggested HMGA2 is an oncogenic molecule promoting malignancy (Supplement Fig. 2 ).
Under a therapeutic dose of γ-irradiation, disruption of DSBs repair by HMGA2 dramatically increased the cytotoxic effect of γ-rays and augmented efficacy of adjuvant radiotherapy in CRCs (Supplement Fig. 2 ). Studies using human samples also revealed that HMGA2 is associated with the CRC response to radiotherapy (Fig. 4C & 4D 
